Alivus Life Sciences Limited (NSE:ALIVUS)

Market Cap	117.58B
Revenue (ttm)	24.00B
Net Income (ttm)	4.96B
Shares Out	122.68M
EPS (ttm)	40.32
PE Ratio	23.77
Forward PE	21.72
Dividend	5.00 (0.52%)
Ex-Dividend Date	Sep 1, 2025

Volume	85,354
Average Volume	84,799
Open	939.00
Previous Close	934.80
Day's Range	920.10 - 943.20
52-Week Range	850.00 - 1,251.00
Beta	0.13
RSI	39.19
Earnings Date	Jul 23, 2025

About Alivus Life Sciences

Alivus Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. The company’s APIs are used in various therapeutic segments, in...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2011
• Employees: 2,014
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ALIVUS

Financial Performance

In 2024, Alivus Life Sciences's revenue was 23.87 billion, an increase of 4.54% compared to the previous year's 22.83 billion. Earnings were 4.86 billion, an increase of 3.13%.